< Back to previous page
Researcher
Thomas Morel
- Disciplines:Gastro-enterology and hepatology, Immunology, Paediatrics and neonatology, Nursing
Affiliations
- Hepatology (Division)
Member
From1 Apr 2019 → 31 Mar 2022 - Clinical Pharmacology and Pharmacotherapy (Division)
Member
From1 Jul 2013 → 31 Mar 2019
Projects
1 - 1 of 1
- Rare diseases and orphan drugs: patient values, market trends and misconceptions.From1 Oct 2013 → 11 Jan 2019Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 22
- Improving Interpretation of Evidence Relating to Quality of Life in Health Technology Assessments of Rare Disease Treatments(2023)
Authors: Thomas Morel
Pages: 7 - 17 - The FATIGUE-PRO: a new patient-reported outcome instrument to quantify fatigue in patients affected by systemic lupus erythematosus(2022)
Authors: Thomas Morel
Pages: 3329 - 3340 - Development of the Myasthenia Gravis (MG) Symptoms PRO: a case study of a patient-centred outcome measure in rare disease(2021)
Authors: Thomas Morel
- The Patient Experience of Fatigue in Systemic Lupus Erythematosus: A Conceptual Model(2021)
Authors: Thomas Morel
Pages: 95 - 108 - Psychometric Analysis from EMBODY1 and 2 Clinical Trials to Help Select Suitable Fatigue PRO Scales for Future Systemic Lupus Erythematosus Studies(2021)
Authors: Thomas Morel
Pages: 1287 - 1301 - SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials(2021)
Authors: Thomas Morel
- Rare diseases and orphan drugs: patient values, market trends and misconceptions.(2019)
Authors: Thomas Morel, Steven Simoens, David Cassiman
- Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group(2018)
Authors: Thomas Morel, Steven Simoens
Pages: 493 - 500 - Measuring what matters to rare disease patients - reflections on the work by the IRDiRC taskforce on patient-centered outcome measures(2017)
Authors: Thomas Morel
- Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012(2017)
Authors: Kim Pauwels, Isabelle Huys, Minne Casteels, Thomas Morel, Steven Simoens